Numenos has raised $5.0M in total across 1 funding round.
Numenos's investors include TechAviv Founder Partners, Ariel Maislos.
Numenos is a technology company specializing in AI-driven solutions to improve drug development and clinical trial outcomes. Their flagship product, the CURE platform, integrates and analyzes real-world data (RWD) and clinical trial data (Phases I-IV) to uncover insights that guide data-driven decision-making, patient stratification, and target discovery. Numenos serves pharmaceutical and biotech companies by addressing the inefficiencies and limitations of traditional drug development methods, aiming to enhance trial power, reduce time to proof of concept, and ultimately improve patient outcomes[1][2][3].
Founded by a multidisciplinary team of entrepreneurs, biologists, physicists, and AI specialists, Numenos emerged from recognizing the need to unlock new possibilities in drug development through advanced AI. The company was bootstrapped initially and focused on validating its technology with clients before scaling. Key figures include co-founder and CTO Amit Weiss, who leads the development of foundational AI models, and CEO Vitalay Fomin, Ph.D., who emphasizes the company’s commitment to precision medicine and individualized patient care[3][4].
Numenos rides the growing trend of applying AI and machine learning to pharmaceutical R&D, particularly in precision medicine and clinical trial optimization. The timing is critical as the pharmaceutical industry increasingly relies on real-world data and AI to reduce costly trial failures and accelerate drug approval processes. Market forces such as rising healthcare costs, demand for personalized therapies, and advances in AI technology favor Numenos’ approach. By improving trial efficiency and patient stratification, Numenos influences the broader ecosystem by enabling more effective drug development and potentially faster delivery of therapies to patients[1][3][4].
Looking ahead, Numenos is poised to expand its impact by further refining its AI models and broadening its application across various disease areas beyond oncology. Trends such as increasing availability of multi-omics data, regulatory acceptance of AI-driven evidence, and the push for personalized medicine will shape their journey. Their influence may evolve from a clinical trial optimization tool to a foundational platform for individualized treatment strategies, potentially transforming how drugs are developed and prescribed[3][4].
In summary, Numenos leverages cutting-edge AI to address critical challenges in drug development, positioning itself at the intersection of technology and healthcare innovation with a clear mission to improve patient outcomes through smarter, data-driven clinical trials.
Numenos has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $5.0M Seed | TechAviv Founder Partners, Ariel Maislos |